TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 8,625 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

TransMedics Group Stock Performance

Shares of TMDX traded down $2.82 during mid-day trading on Thursday, hitting $127.15. The stock had a trading volume of 1,010,356 shares, compared to its average volume of 833,459. The firm has a market cap of $4.24 billion, a P/E ratio of 3,249.25 and a beta of 1.99. The business has a fifty day moving average price of $154.12 and a 200-day moving average price of $137.55. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The firm had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business’s revenue was up 117.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.03) earnings per share. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.22 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Needham & Company LLC assumed coverage on TransMedics Group in a report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a report on Monday, October 7th. Stephens lifted their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group lifted their price target on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $174.30.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in the stock. Amalgamated Bank grew its position in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares in the last quarter. Pitcairn Co. grew its position in shares of TransMedics Group by 1.5% in the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after purchasing an additional 78 shares in the last quarter. Harbour Capital Advisors LLC grew its position in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares in the last quarter. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after purchasing an additional 186 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.